Free Republic

Lowering cholesterol far below the level that most doctors now consider adequate can substantially reduce patients' risk of having or dying from a heart attack, researchers reported today. The findings, cardiologists say, will greatly change how doctors treat patients with heart disease and will provide the impetus to re-evaluate how low cholesterol levels should be. The study compared high doses of one of the most powerful cholesterol-lowering drugs, Pfizer's Lipitor, to a less potent drug, Pravachol, made by Bristol-Myers Squibb, which conducted the trial. The patients taking Lipitor were significantly less likely to have heart attacks or to require bypass...

June 15, 2002 | 11:42 AM The Wacky Dr. Waksal by Frank DiGiacomo and Ian Blecher On Dec. 5, 2001, ImClone Systems, a biotech company that was seeking Food and Drug Administration approval for a promising anti-cancer drug called Erbitux, saw its stock peak at a price of $74 a share and begin an earthward trajectory. On the evening of Dec. 6, ImClone’s chief executive, Sam Waksal, 54, threw his annual Christmas party at the 5,000-square-foot Thompson Street loft that he calls home. Daily News owner Mort Zuckerman was in attendance, as well as former New York Times executive editor...